Tempest Therapeutics Inc (TPST) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of -0.536x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.57 Million) by net assets ($6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tempest Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Tempest Therapeutics Inc (TPST) total liabilities for a breakdown of total debt and financial obligations.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Despec Bilgisayar Pazarlama ve Ticaret AS
IS:DESPC
|
1.798x |
|
SCI Electric Public Company Limited
BK:SCI
|
0.031x |
|
Sun Peak Metals Corp
V:PEAK
|
-0.055x |
|
Scandinavian Enviro Systems AB
ST:SES
|
-0.051x |
|
Rossell India Limited
NSE:ROSSELLIND
|
-0.043x |
|
Seoul Electronics & Telecom Co. Ltd
KQ:027040
|
-0.173x |
|
Lyckegard Group AB
ST:LYGRD
|
0.380x |
|
Gromutual Bhd
KLSE:9962
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see TPST stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.67 Million | $-26.82 Million | -4.022x | -132.93% |
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule du… Read more